Last €65.57 EUR
Change Today -0.433 / -0.66%
Volume 0.0
6COP On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 2:20 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (6COP) Snapshot

Open
€66.03
Previous Close
€66.00
Day High
€66.03
Day Low
€65.57
52 Week High
06/16/14 - €72.60
52 Week Low
10/7/13 - €43.29
Market Cap
29.6B
Average Volume 10 Days
192.5
EPS TTM
--
Shares Outstanding
451.5M
EX-Date
07/25/14
P/E TM
--
Dividend
€1.28
Dividend Yield
1.36%
Current Stock Chart for COVIDIEN PLC (6COP)

covidien plc (6COP) Related Businessweek News

View More BusinessWeek News

covidien plc (6COP) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company’s Medical Devices segment develops, manufactures, and sells endomechanical instruments, such as laparoscopic instruments, surgical staplers, and interventional lung solutions; energy devices, including vessel sealing, electrosurgical, and ablation products and related capital equipment; and soft tissue repair products comprising sutures, mesh, biosurgery products, and hernia mechanical devices. This segment also offers vascular products, such as compression, dialysis, venous insufficiency, thrombectomy, neurovascular, and peripheral vascular products; oximetry and monitoring products, including sensors, monitors, and temperature management products; and airway and ventilation products comprising airway, ventilator, breathing systems, and inhalation therapy products. Its products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. The company’s Medical Supplies segment develops, manufactures, and distributes nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products; medical surgical products, such as operating room supply products related accessories, electrodes, thermometry, and chart paper product lines; SharpSafety products, including needles, syringes, and sharps disposal products; and original equipment manufacturer products. Its products are used primarily in hospitals, surgi-centers, and alternate care facilities, such as homecare and long-term care facilities. The company markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

38,500 Employees
Last Reported Date: 11/21/13

covidien plc (6COP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $783.5K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and General Counsel
Total Annual Compensation: $580.9K
Compensation as of Fiscal Year 2013.

covidien plc (6COP) Key Developments

Covidien plc Appoints Bryan Hanson as President, Effective from Oct. 1, 2014

Covidien plc announced that Bryan Hanson, who currently serves as group president, Medical Devices & U.S., will be elevated to the newly created position of group president, Covidien, effective Oct. 1, 2014. In this role, Hanson will have global responsibility for all Covidien business segments. Hanson has overseen the company's Surgical Solutions, Vascular Therapies and Respiratory & Monitoring Solutions business units, as well as its Health Systems organization, since October 2013. He recently assumed oversight of the company's Emerging Markets business and will add responsibility for the company's Developed Markets and Medical Supplies businesses when his appointment becomes effective. Hanson joined Covidien in 1992 and has held positions of increasing responsibility in sales, marketing and general management. Prior to being appointed group president, Medical Devices & U.S., Hanson served as group president, Surgical Solutions, and president, Energy-based Devices.

Covidien plc Declares Quarterly Cash Dividend, Payable on August 19, 2014

Covidien plc announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per ordinary share. The dividend is payable on August 19, 2014, to shareholders of record on July 29, 2014.

Covidien plc Unveils Emprint Ablation System

Covidien plc has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. The Emprint(TM) Ablation System with Thermosphere(TM) Technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumors. Liver tumor ablation with Emprint(TM) Ablation System can be performed without invasive surgery by inserting the system's antenna into the tumor directly through the skin. The physician utilizes ultrasound or CT scanning to guide the antenna. The Emprint Ablation System provides clinicians three kinds of spatial energy control thermal, field and wavelength to create predictable and spherical ablation zones regardless of target location, tissue type, or changes in tissue properties during a procedure. Covidien's advanced ablation system can be used in three different procedure settings including non-surgical procedures directly through the skin, minimally invasive surgery and open surgery. The company expects to fully launch the Emprint system in the United States and the European Union during the current quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6COP:GR €65.57 EUR -0.433

6COP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $218.68 USD -0.95
Baxter International Inc $77.00 USD +0.16
Becton Dickinson and Co $118.49 USD -0.12
Kimberly-Clark Corp $109.49 USD -0.01
Stryker Corp $80.79 USD -1.02
View Industry Companies
 

Industry Analysis

6COP

Industry Average

Valuation 6COP Industry Range
Price/Earnings 25.7x
Price/Sales 3.9x
Price/Book 4.2x
Price/Cash Flow 25.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit www.covidien.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.